Seaport Therapeutics announced positive results from its ongoing Phase 1 trial of GlyphAgo, an experimental treatment for generalized anxiety disorder ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE